A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma

Primary Objective

Phase 1: To assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine. Phase 2: To assess preliminary efficacy as determined by overall response rate (ORR).

Is this Study for You?

Let's Get Started!



Type of Study



CTRC Inpatient
University of Colorado Hospital

Principal Investigator
Photograph of Brad Haverkos,  MD

Brad Haverkos, MD

Study ID

Protocol Number: 22-1202

More information available at ClinicalTrials.gov: NCT05403450


Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers